Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
about
Does HAART efficacy translate to effectiveness? Evidence for a trial effectTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesA conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma CareART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremiaEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenThe role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance.25 years of HIV-1 research - progress and perspectives.Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataEffects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South AfricaAntiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.Outcomes after virologic failure of first-line ART in South AfricaEfficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.HIV infection.Minority variants of drug-resistant HIV.Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort studyAntiretroviral therapies in women after single-dose nevirapine exposure.Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Antiretroviral treatment of HIV infected adultsFirst-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.HIV protease inhibitors and obesityEfficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational databaseCardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir)HIV and HAART-Associated DyslipidemiaA randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.Patient and provider-reported symptoms in the post-cART era.
P2860
Q21135313-EF56708F-4777-4952-B879-C30FF717CC3AQ24656950-A4C5CEA7-8373-4C90-BCF7-CE4BB6F36892Q26851160-5234EDCA-AE2E-4911-9741-E1FFA78F87E6Q28469175-6F01F5FA-EF40-454E-9588-18F63406EA59Q28471623-E78D71F7-7804-48DE-BD56-9857405D3C1DQ28481468-3B683CEE-66B6-42E0-84FB-565CCA650452Q28741214-B8D044A4-ED94-45AF-8CE1-631EF01AFE8DQ30343901-1D0A6F68-1B83-4ACC-A6B5-F90BC07FDB32Q33186873-88B7BDB8-9A85-46A4-A2A0-BC1443FBBCA0Q33249816-7BE28223-FC91-438F-BD9A-DB3DD3D50222Q33258171-E4E51828-7F67-42DD-92AF-9940173FE5CEQ33381841-21D90F3B-7C24-4248-B288-59A9921E7669Q33622168-FE1DE68C-4FC2-4E1A-B581-C0A5A56B388CQ33649563-F6BF97F9-F111-49AB-9CD5-12C8161BE4B0Q33805619-4262D997-03FE-4D68-BF82-E2C5829EB78FQ33811876-51DC052F-4635-4675-820A-777410A20B7FQ33891656-5C44C2D0-7C6B-4FEF-A5CA-31B48A8D9C15Q33893057-C5641038-DF48-49AE-BD40-5D14D3F58603Q33917546-A01E271B-2906-4661-BC1C-BFECBD4FC09AQ33985234-ED9E36CE-988C-41C5-BBF3-9C1D71D2930CQ33988155-F262D49B-0AB5-4DEF-8B2B-50D8A94EDFB8Q34011172-D904897E-4358-4E62-82C0-4958A5F5DC6EQ34047780-70EBFBA4-D82D-4414-970D-018541EC9CF8Q34087809-46DC5496-CAC0-4539-A2CB-ECFB57E5C303Q34103495-14A19681-AEEB-4593-9D1C-FD87DAB82F6AQ34134900-D231D109-377B-41B8-AC7E-90915EC63986Q34292138-DF459B52-1824-4E6C-B099-BD400A3B3608Q34363980-CE3D4E0C-F726-404F-937D-217A7ED7767BQ34546011-1E4D4745-5CEC-42BB-A39D-040C1FA8AD6FQ34631149-7DC5FEC7-E747-49AA-980F-427F1F937432Q34693248-ED0CE93C-4247-43E0-A229-3D64AF4BBEE7Q34748599-68CA7244-1132-4570-887E-51BEB20585EBQ34776414-4CD1962B-554B-49D5-9F7A-F92A353280C1Q34792983-02634951-0CDD-44FC-891B-EC261175AB75Q34977431-CA692EA9-3CD6-4A04-8671-B5095A0DDE7FQ35009815-7603F56B-1C65-427F-8367-2A7BC8AED1A8Q35020217-5DC4AC8F-4D0F-4517-A0A6-8C0275F30EE9Q35024683-1F66E317-FD90-441E-B0FB-19A2629A4EEBQ35034306-16E22087-8A70-4EA2-AD5B-E4A7F1AC0E82Q35055102-CEA54BF3-6697-4EED-AC8B-2012F3E97971
P2860
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@en
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@nl
type
label
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@en
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@nl
prefLabel
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@en
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
@nl
P2093
P356
P1476
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
@en
P2093
Anthony Japour
Barry Bernstein
David Johnson
Eugene Sun
Gildon Beall
M98-863 Study Team
Margaret Johnson
Martin King
Peter Ruane
Richard Lalonde
P304
P356
10.1056/NEJMOA012354
P407
P577
2002-06-01T00:00:00Z